Fritextsökning
Innehållstyper
-
Fast Optical Sectioning of Developing Organisms and Tissue Microstructures
ZEISS Lattice SIM 3 exploits the full potential of the SIM Apotome technology.
-
The new Swedish life science strategy – “It will consolidate Sweden as a leader”
Clinical trials and precision health are emphasised as key areas in the new national life science strategy.
-
In search of Marcel Proust's lost health
A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...
-
AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence
AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.
-
KI-studie: Nässköljning kunde ge information om KOL
Förekomsten av ett visst protein i näsan kunde användas som underlag för bedömning av KOL, i en ny studie från forskare vid Karolinska institutet.
-
Medivir CEO on upcoming study: ”It's about working together with others”
Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...
-
The Crucial Role of Core Imaging Facility Managers
User story from ZEISS and the University of York.
-
A new life science cluster formed – “We are very strong in talent”
Stockholm and Uppsala’s joint life science cluster aims to be among the best in Europe. Pontus Holm, Life Science Coordinator for Region Stockholm, says the dec...
-
Mavatar AB
-
Investigations against AstraZeneca: ”Chinese interests may be behind them”
Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.
-
High-performance Slide Scanner for Fluorescence, Brightfield and Polarization
ZEISS Axioscan 7 combines high speed digitization and outstanding image quality.
-
HAB Nicolai Johannsen
-
Cytel Inc acquires the SDS Group
The multinational statistical software developer and contract research organization Cytel Inc, headquartered in Massachusetts, USA, acquires the Swedish consult...
-
40,000 DNA extractions daily
It's great when things run quickly: 20 minutes per extraction process and a new plate every 2.5 minutes – the Dutch company Synchron Lab Automation, in cooperat...
-
Lilly´s Nordic manager on Mounjaro launch in Sweden: "Patients deserve respect"
Another blockbuster diabetes and obesity drug has made its way into the Swedish market – with promises of a stable supply and availability for patients. “What w...
-
Roche’s Genentech terminates licencing deal with Norwegian biotech
Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.
-
How to avoid measurement inaccuracies due to wear
Expert tip from ZEISS.
-
”The importance of stratification in a statistician’s August kitchen”
Ingrid Lönnstedt writes about an experiment of her own at home and about what lessons can be learned from it, in a science column.
-
Specific proposals and targets top the universities’ desired priorities
What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Kar...
-
MSD discontinues development of cancer drugs after trial failures
MSD suspends Phase 3 trials for two drug programs for different forms of cancer after trial failures.
-
Accurate removal of prostate tissue
Medical robots play an important role in diagnostics
-
Christina Östberg Lloyd satsar på eget – ”Jag är full av energi”
Efter över tjugo år på olika tjänster inom life science-företag satsar Christina Östberg Lloyd på eget som konsult. ”Detta öppnar upp helt nya perspektiv och mö...
-
He takes over the chairmanship of Karolinska Development
Ben Toogood is appointed as the new chairman of Karolinska Developments.
-
Her company is developing a new tablet form obesity drug
Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...